You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Novartis presents positive new data on relapsing MS treatment

Novartis has announced new long-term data from the phase 3 Asclepios trials into Kesimpta (ofatumumab) for patients with relapsing multiple sclerosis (RMS), following up to four years of treatment.